SCHEMBL2783455

SCHEMBL2783455

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1C(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
ALDH1A1 P00352 8/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.45
POLB P06746 1/20 0.45
MDM2 Q00987 1/20 0.45
RECQL P46063 1/20 0.45
MAT2A P31153 1/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
KDM4E B2RXH2 3/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2780881 0.95 ALDH1A1 (0.46) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2779066 0.93 MAPT (0.46) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2781037 0.90 LMNA (0.45) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2780006 0.90 ALDH1A1 (0.43) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2780206 0.88 CYP1A2 (0.48) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2780046 0.87 MAPT (0.43) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL16474394 0.86 MAPT (0.54) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2782824 0.86 ALDH1A1 (0.44) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2960195 0.84 ALDH1A1 (0.56) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL1265759 0.84 MAPT (0.52) MAPTALDH1A1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795256-B2 Thieno-pyridinone derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2010-09-14 US claimed
US-20070078131-A1 Thieno-pyridinone derivatives as kinase inhibitors CELLTECH R&D LIMITED (GB) 2007-04-05 US claimed
US-7795256-B2 Thieno-pyridinone derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2010-09-14 US disclosed
US-20070078131-A1 Thieno-pyridinone derivatives as kinase inhibitors CELLTECH R&D LIMITED (GB) 2007-04-05 US disclosed
EP-1680429-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS Celltech R & D Limited (GB) 2006-07-19 EP disclosed
WO-2005042540-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078131-A1 Thieno-pyridinone derivatives as kinase inhibitors MAP3K6, MAP4K2, MAP3K15 MAPT 1567/4885ALDH1A1 2586/4885KMT2A 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.